Gilead Ends Trial of Novel Drug for Rare Lung Disease
This article is for subscribers only.
Gilead Sciences Inc., the world’s biggest maker of AIDS drugs, said it is stopping a late-stage study of an experimental lung-disease therapy because it didn’t help patients with the condition, idiopathic pulmonary fibrosis.
The drug, ambrisentan, was in the final stage of testing usually required for U.S. approval, the Foster City, California-based company said in a statement today. The decision to halt the study followed an interim analysis of data by a monitoring committee and the company’s review, according to the statement.